1. Psidial A shows activity to enzyme PTP1B.
2. Psidial A reduces tumor growth and stimulate uterus proliferation.
Calycosin, a selective estrogen receptor modulator, is also a vasorelaxant and a noncompetitive Ca(2+) channel blocker. It has anti-oxidative, anti-inflammatory, hepatoprotective,antineoplastic, and effective skin-lightening activities. Calycosin exhibited tyrosinase inhibitory activity with an IC(50) value of 38.4 microM, it suppressed breast cancer cell growth via ERβ-dependent regulation of IGF-1R, p38 MAPK and PI3K/Akt pathways.
Liquiritigenin, is an estrogenic compound which acts as an agonist selective for the β-subtype of the estrogen receptor, possesses anti-inflammatory, antihyperlipidemic, and antiallergic effects. Liquiritigenin can dose dependently alleviate mechanical, thermal and cold hyperalgesia, it may be potentially useful novel treatments for neuropathic pain. It exhibits antitumour action in pituitary adenoma cells via Ras/ERKs and ROS-dependent mitochondrial signalling pathways.
1. Hinokiresinol (trans-hinokiresinol) and nyasol (cis-hinokiresinol) possess appreciable estrogen receptor binding activity, they can stimulate the proliferation of estrogen- dependent T47D breast cancer cells, and their stimulatory effects could be blocked by an estrogen antagonist, indicating that they are estrogen agonists.
2. trans- and cis-Hinokiresinols have similar free radical scavenging and anti-inflammatory activities, they also have anti-ischemic effects, only trans-hinokiresinol can significantly decrease neuronal injury in cultured cortical neurons exposed to oxygen-glucose deprivation followed by re-oxygenation.
3. Hinokiresinol is a novel inhibitor of LTB4 binding to the human neutrophils.
4. Hinokiresinol has antiallergic effect, it inhibits IgE-induced mouse passive cutaneous anaphylaxis reaction.
1. Medicarpin, a legume phytoalexin, acts as an estrogen receptor (ER) agonist, can stimulate osteoblast differentiation likely via ERβ, promote achievement of peak bone mass, and is devoid of uterine estrogenicity; in addition, given its excellent oral bioavailability, it can be potential osteogenic agent.
2. Medicarpin exhibits no uterine estrogenicity, however it can inhibit osteoclastogenesis and has nonestrogenic bone conserving effect in ovariectomized mice.
3. Medicarpin and maackiain and two of their biosynthetic precursors inhibit the constitutive and phenobarbital (PB)-induced types of AHH, but have little effect on the 3-methylcholanthrene (MC)-induced type of AHH.
4. Medicarpin sensitizes myeloid leukemia cells to TRAIL-induced apoptosis through the induction of DR5 and activation of the ROS-JNK-CHOP pathway.
5. Medicarpin has antifungal activity.